课题基金 / 基金详情

Novel regulation of insulin action in the liver

Novel regulation of insulin action in the liver
肝脏中胰岛素作用的新调节
批准号:
10549322
负责人:
Bo Wang
金额:
$33.4万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-02-01 至 2027-01-31

项目摘要

项目成果

Bo Wang的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY Insulin resistance and type 2 diabetes mellitus (T2DM) have presented an enormous burden to public health and economy with increasing prevalence. T2DM is characterized by relative insulin deficiency caused by pancreas β cells dysfunction and insulin resistance in metabolic organs. The liver plays a central role in regulating systemic glucose and lipid homeostasis. Aberrant hepatic insulin action is believed to be a primary driver of insulin resistance, in which insulin fails to adequately suppress hepatic glucose production (HGP), while enhances lipogenesis and triglyceride secretion, a phenomenon referred to as selective insulin resistance. Although downstream signaling cascades mediating insulin's control of glucose and lipid metabolism have been extensively studied, the molecular mechanisms underlying the development of insulin resistance and its differential effect on glucose and lipid metabolism are not well understood. We previously have identified critical functions of lysophosphatidylcholine acyltransferase 3 (Lpcat3), a phospholipid (PL) remodeling enzyme, in lipid metabolism in liver. Loss of Lpcat3 selectively reduces polyunsaturated PL in membranes, leading to decreased membrane fluidity and curvature. Changes in membrane dynamics result in impaired SREBP-1c processing and lipogenesis, and reduced triglyceride secretion in liver. The overall goal of this proposal is to define the roles of hepatic Lpcat3 and PL composition in insulin signaling and systemic lipid and glucose metabolism, and their contribution to the development of insulin resistance. In Aim 1, we will elucidate the mechanisms by which PL composition regulates insulin sensitivity. In Aim 2, we will investigate whether dysregulation of Lpcat3 expression mediates selective insulin resistance in T2DM. In Aim 3, we will test the therapeutic potential of targeting Lpcat3 for hyperglycemia and hypertriglyceridemia in T2DM. The results of this work will advance our understanding of how membrane composition modulates insulin sensitivity and glucose metabolism in liver, and how changes in membrane biophysical properties contribute to the pathogenesis of insulin resistance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel regulation of insulin action in the liver
Comparative systems biology defines regulatory mechanisms in whole-body regeneration
  • 批准号:
    10248519
  • 项目类别:
  • 资助金额:
    $39.33万
  • 财政年份:
    2020
  • 负责人:
    Bo Wang
  • 依托单位:
Comparative systems biology defines regulatory mechanisms in whole-body regeneration
  • 批准号:
    10434946
  • 项目类别:
  • 资助金额:
    $39.33万
  • 财政年份:
    2020
  • 负责人:
    Bo Wang
  • 依托单位:
Comparative systems biology defines regulatory mechanisms in whole-body regeneration
  • 批准号:
    10028253
  • 项目类别:
  • 资助金额:
    $39.33万
  • 财政年份:
    2020
  • 负责人:
    Bo Wang
  • 依托单位:
海外基金